Drug Trial Radar · NCT07266467
Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients
Last checked: Nov 20, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
290
Planned (sponsor's estimate)
Start
May 13, 2025
Primary completion
Nov 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Chinese People's Liberation Army Northern Theater Command General Hospital; The First Hospital of Jilin University; The Affiliated Hospital of Qingdao University; Qianfo Mountain Hospital, Shandong Province; The First Affiliated Hospital of Anhui Medical University; Eastern Theater General Hospital; Shu lan Hospital; Shanghai Zhongshan Hospital; Tongji Hospital; The Second Xiangya Hospital, Central South University; The First Affiliated Hospital of Zhengzhou University; Second Affiliated Hospital of Guangzhou Medical University; First Affiliated Hospital, Sun Yat-Sen University; Beijing Chao Yang Hospital; RenJi Hospital; Nanfang Hospital, Southern Medical University; Beijing Tsinghua Changgeng Hospital
- First posted
- Dec 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
the existing anti-CMV drugs mainly include valganciclovir, ganciclovir and foscarnet sodium, all of which act on DNA polymerase (pUL54), making them prone to cross resistance. DNA synthesis in normal cell is also catalyzed by DNA polymerase, which can also inhibit normal cell production, especially in metabolically active bone marrow cells, leading to bone marrow suppression. In addition, these drugs are mainly metabolized by the kidneys, causing damage to proximal renal tubular cells. Therefore, it is necessary to closely monitor the patient's renal function and adjust the dosage. Overall, the medical demand for effective and well-tolerated treatment methods for CMV infection management in kidney transplant recipients remains unmet, and safer anti-CMV drugs are urgently needed. The target of letemovir is the CMV DNA terminal enzyme complex, which is different from the target of existing anti-CMV drugs, and does not exhibit cross resistance. Moreover, this target does not have a corresponding substance in mammalian cells and does not exhibit toxicity similar to DNA polymerase targets. In addition, letemovir is mainly metabolized by the liver, and urinary excretion can be ignored (\<2% dose), so there is no need to adjust the dose according to renal function. Phase III registered clinical studies abroad have shown that letemovir is not inferior to valganciclovir in preventing CMV disease in kidney transplant recipients. Additionally, letemovir is safer and has a lower incidence of adverse reactions, especially leukopenia or granulocytopenia. However, there is still a lack of data on the use of kidney transplantation in Chinese population. The aim of this study was to evaluate the efficacy and safety of letamovir in preventing CMV infection and CMV disease in kidney transplant recipients in China.
Conditions
- Kidney Transplant
Interventions
LetermovirDrug
Drug name: Letermovir.
ValganciclovirDrug
Valganciclovir.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of CMV disease at 52 weeks after transplantationTime frame: 52 weeks after transplantation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Xi 'an Jiaotong University
Xi'an, Shaanxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.